Table 1.
Baseline characteristics in all patients in the intention-to-treat population by status at 180 days and intervention group (12 mg or 6 mg of dexamethasone) in the COVID STEROID 2 trial
| Dead at 180 days | HRQoL respondentsa | Missing HRQoL datab | ||||
|---|---|---|---|---|---|---|
| 12 mg (n = 164) | 6 mg (n = 184) | 12 mg (n = 298) | 6 mg (n = 276) | 12 mg (n = 35) | 6 mg (n = 25) | |
| Country of enrolment, n (%) | ||||||
| Denmark, n = 485 | 66 (40%) | 77 (42%) | 157 (53%) | 142 (51%) | 28 (80%) | 15 (60%) |
| India, n = 369 | 82 (50%) | 87 (47%) | 98 (33%) | 96 (35%) | 2 (6%) | 4 (16%) |
| Sweden, n = 79 | 10 (6%) | 8 (4%) | 26 (9%) | 25 (9%) | 4 (11%) | 6 (24%) |
| Switzerland, n = 49 | 6 (4%) | 12 (7%) | 17 (6%) | 13 (5%) | 1 (3%) | 0 |
| Age, years | 71 (64–76) | 69 (60–75) | 61 (53–69) | 61 (52–70) | 61 (52–69) | 55 (47–71) |
| Weight, kg | 73 (63–88) | 75 (65–90) | 85 (70–100) | 80 (70–96) | 85 (70–101) | 91 (78–97) |
| Co-morbidities, n (%) | ||||||
| Diabetes | 55 (34%) | 65 (35%) | 74 (25%) | 93 (34%) | 6 (17%) | 5 (20%) |
| Ischaemic heart disease | 30 (18%) | 34 (19%) | 34 (11%) | 34 (12%) | 3 (9%) | 1 (4%) |
| Pulmonary disease | 20 (12%) | 28 (15%) | 34 (11%) | 28 (10%) | 3 (9%) | 0 |
| Immunosuppression | 21 (13%) | 29 (16%) | 18 (6%) | 12 (4%) | 1 (3%) | 2 (8%) |
| Co-interventions, n (%) | ||||||
| Chronic corticosteroid use | 6 (4%) | 13 (7%) | 7 (2%) | 2 (1%) | 0 | 1 (4%) |
| Limits of care | 22 (13%) | 19 (10%) | 6 (2%) | 6 (2%) | 2 (6%) | 0 |
| Invasive mechanical ventilation | 46 (28%) | 48 (26%) | 52 (17%) | 47 (17%) | 9 (26%) | 4 (16%) |
| Vasopressor or inotrope | 30 (18%) | 35 (19%) | 43 (14%) | 30 (11%) | 8 (23%) | 3 (12%) |
| Renal replacement therapy | 6 (4%) | 10 (5%) | 4 (1%) | 3 (1%) | 1 (3%) | 1 (4%) |
| Anti-inflammatory drugs | 15 (9%) | 16 (9%) | 40 (13%) | 38 (14%) | 3 (9%) | 3 (12%) |
| IL-6-RA | 13 (8%) | 9 (5%) | 36 (12%) | 35 (13%) | 3 (9%) | 3 (12%) |
Numeric data are presented as medians with interquartile ranges
IL-6-RA interleukin-6-receptor antagonist
aIncluding responses from patients (n = 503) and relatives on behalf of patients (n = 73); 2 patients included here only had complete EQ VAS data and not complete EQ-5D-5L index value data
bIncluding non-respondents (22 in 12 mg group and 17 in the 6 mg group) and those with no HRQoL data available (patients with partially available HRQoL data were included as respondents)